Some CD4+T cells of patients with RA who respond to ADA therapy have the characteristics of upregulation of TNF signaling pathway-related genes, such as CTLA4, TNFSF13B, TNFRSF1B, TNFSF4, IRF1, and IL18R1. This evidence concerns the gene CD4 and rheumatoid arthritis.